Skystar Bio-Pharmaceutical Reports Second Quarter 2012 Results
Revenues of $8.9 Million; Net Income of $1.7 Million; $0.23 Diluted EPS; Xi'an Veterinary Medication Facility Expected to Resume Production Third Quarter
(firmenpresse) - XI'AN, CHINA -- (Marketwire) -- 08/14/12 -- (NASDAQ: SKBI) a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited second quarter fiscal year 2011 earnings, for the period ended June 30, 2011.
Revenue decrease slightly 2.5% YoY to $8.9 million
Micro-organism products totaled $4.0 million, up 102.0% YoY
Veterinary medicines totaled $2.5 million, a decrease of 61.2% YoY
Feed additives totaled $1.3 million, up 224.2% YoY
Veterinary vaccines totaled $1.1 million, up 199.0% YoY
Gross margin of 57.8% for the second quarter of fiscal 2011 as compared to 49.0% in the year ago period
Net income of $1.7 million or $0.23 per fully diluted share, compared with net income of $1.5 million or $0.21 per fully diluted share in the year ago period
First half fiscal 2012 revenue increases 3.8% YoY to $16.8 million
Gross margin of 56.0% for the first half of fiscal 2012 as compared to 49.8% in the year ago period
Net income of $3.6 million or $0.48 per fully diluted share, compared with net income of $3.4 million or $0.48 per fully diluted share in the year ago period
Mr. Weibing Lu, Skystar Bio-Pharmaceutical's chairman and chief executive officer, commented, "Skystar made significant progress in the second quarter of fiscal 2012 in its evolution to scale up its business. During the period, Skystar has been able to maintain fiscal profitability, control raw materials costs and operating expenses while moving forward with efforts to modernize and automate manufacturing of its veterinary vaccine, medication, probiotic and feed additives lines.
"In order to maintain revenue and profit in a 'GMP certification' year for several of Skystar's production facilities, Management has ramped sales and marketing for other parts of the business and introduced various customer concession and retention programs to compensate for a reduced supply of veterinary medicine products and not have to reduce the price of products to customers.
"As previously announced on June 26, 2012, China's Ministry of Agriculture (MOA) experts' physically inspected the Company's Huxian veterinary medicine manufacturing plant and published its recommendation to renew Skystar's GMP certificate, valid for a period of five years. While the Company awaits post-inspection procedures from the MOA, the veterinary medicine plant in Huxian remains closed. Skystar anticipates the renewed GMP certificate will be physically received in the third quarter of 2012. During this time, the Company successfully shifted its sales strategy temporarily to other product lines, mainly probiotics and feed additives. The goal of this exercise was not only to maintain revenue guidance but to take the opportunity to further inroads in expanding the sales footprint of its probiotics line whose record sales doubled as compared to the same period a year ago.
"Operationally, the Compared pared back research and development activities, primarily moving forward with projects that were paid for already in previous years. As the GMP recertification at Huxian's veterinary medicine facility heads closer towards full production the Company anticipates increasing efforts and investment in research and development at that juncture.
"Management is excited to share its results at the half year mark. Skystar has been able to successfully implement its operational strategy as it moves towards the most profitable half of the fiscal year. We believe that the course management has plotted will position Skystar to make forecasted fiscal guidance for 2012 and to position the Company for revamped growth in fiscal 2013," concluded Mr. Lu.
Skystar reported second quarter fiscal year 2012 revenues of $8,870,848 as compared to revenues of $9,096,141 for the comparable year ago period, a decrease of $225,293 or 2.5%. This was in line with management's internal forecast due to there being no production at Huxian veterinary medication plant during the quarter for GMP re-examination.
Cost of revenue, which consists of raw materials, direct labor, and manufacturing overhead for our four product lines, was $3,746,938 for the three months ended June 30, 2012, as compared to $4,637,007 for the three months ended June 30, 2011, a decrease of $890,069 or 19.2%, as a result of decreased sales of our veterinary medications product line.
Gross profit was $5,123,910 for the three months ended June 30, 2012, a 15.0% year over year increase as compared to $4,459,134 for the three months ended June 30, 2011. Gross margin for the period was 58% due to selling higher margin products for the period.
Operating Expenses
Research and development costs totaled $330,532 for the three months ended June 30, 2012 as compared to $1,801,551 for the three months ended June 30, 2011, a decrease of $1,471,019 or 81.7%. The decrease was primarily due to less R&D efforts undertaken during the second quarter of 2012 as compared to the same period of 2011.
Selling expenses totaled $670,567 for the three months ended June 30, 2012 as compared to $609,826 for the three months ended June 30, 2011, an increase of $60,741 or 10.0%. This increase is primarily a result of increased shipping and handling costs related to delivering our products to customers as we continued to expand our market to remote areas, and to increased number of units to be shipped. Shipping and handling costs totaled $463,630 and $350,054 for the three months ended June 30, 2012 and 2011, respectively, an increase of $113,576 or 32.4%.
General and administrative expenses totaled $1,834,280 for the three months ended June 30, 2012 as compared to $515,293 for the three months ended June 30, 2011, an increase of $1,318,987 or 256.0%.
As of June 30, 2012, we had cash of $2,341,981. Our total current assets were $68,680,543, and our total current liabilities were $19,159,602, which resulted in a net working capital of $49,520,941.
We currently reiterate our fiscal 2012 guidance to be in the range of $53 million to $57 million for the full year.
Skystar will host a conference call at 7:45 a.m. ET on Wednesday, August 15, 2012 to review the Company's second quarter financial and operational performance. Mr. Weibing Lu, Skystar's chairman and chief executive officer, will host the call, which will be webcast live.
The webcast will be made available on the investor relations section of the Skystar corporate website at .
Telephone access to the conference call will be available in North America by dialing +1 (877) 407-8031 or internationally by dialing +1 (201) 689-8031.
An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, using replay account code # 286 and conference ID # 398886.
An archived replay of the conference webcast will also be available on investor relations section of the Skystar corporate website at .
To be added to the Company's email distribution for future news releases, please send your request to .
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 284 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit .
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the Company's ability to receive timely certification and related government approvals, effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
Scott Cramer
Director - Corporate Development and U.S. Representative
(407) 645-4433
Christopher Chu
(646) 284-9426
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.08.2012 - 20:20 Uhr
Sprache: Deutsch
News-ID 174620
Anzahl Zeichen: 0
contact information:
Town:
XI'AN, CHINA
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Skystar Bio-Pharmaceutical Reports Second Quarter 2012 Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Skystar Bio-Pharmaceutical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
